2 Millionaire-Maker Stocks to Hold for the Next 10 Years

The article argues Alphabet and Eli Lilly still have strong long-term upside, driven by AI-enabled growth in Google Search, cloud, YouTube, Waymo, and Eli Lilly’s AI drug discovery efforts. It highlights Alphabet’s diversified business and Eli Lilly’s pipeline and obesity franchise as reasons both stocks could outperform through 2036. This is opinion-driven commentary rather than a new catalyst, so near-term market impact should be limited.

Analysis

The market is likely still underpricing the durability of both moats because the narrative frames them as “already winners,” which tends to compress forward multiples even when incremental ROI on capital remains attractive. For Alphabet, the second-order benefit is not just ad monetization from AI-enhanced search, but a broader re-acceleration in internal cash recycling: excess cash flow can continue funding cloud, video, and autonomy without forcing balance-sheet strain. That creates a rare setup where capex intensity can look scary in the near term while actually extending the duration of the moat over a 3-5 year horizon.

The more interesting takeaway is competitive displacement, not absolute growth. If AI search improves user retention, smaller ad-tech intermediaries and lower-quality content aggregators likely get squeezed first, while YouTube and cloud capture the demand reallocation. In autos, Waymo’s advantage is less about being first to autonomy and more about being first to operational density; that makes partnerships and geofenced expansion the key swing factor, with the real monetization window likely still 12-24 months out rather than immediate.

For Eli Lilly, the consensus is too focused on the obvious obesity franchise and not enough on pipeline timing optionality. AI drug discovery matters most if it shortens iteration cycles by even 10-15%, because in pharma small time gains can translate into materially longer peak sales windows before exclusivity erosion. The biggest risk is not scientific failure alone, but investor disappointment if the AI initiative produces process efficiency without obvious near-term revenue attribution, which could leave the stock exposed to multiple compression after any trial or regulatory hiccup.

The broader contrarian angle is that both names remain quality compounders, but the easy money may require patience: Alphabet monetization inflects over several quarters, while Lilly’s AI upside is a multi-year call option embedded in a high-expectation stock. The trade is therefore less about chasing momentum and more about using any volatility around capex or pipeline headlines to add exposure, because the fundamental rerating, if it comes, should happen over months to years rather than days.

Key Decisions for Investors

• Long GOOG/GOOGL on weakness over the next 1-3 weeks; best entry is any pullback tied to capex or cloud-margin anxiety. Risk/reward favors a 12-18 month hold because AI/search and YouTube monetization can support another leg of FCF growth even if near-term margins stay pressured.
• Add LLY on post-catalyst drawdowns rather than breakouts. Use a 6-12 month horizon and expect volatility; the asymmetric upside comes from pipeline expansion plus AI-driven R&D efficiency, while the main risk is multiple compression if execution appears merely “good” instead of exceptional.
• Pair long GOOG vs short a weaker AI monetization beneficiary in ad-tech or legacy search-ad exposure for a 3-6 month relative-value expression. The thesis is that platform owners with distribution and compute will capture more of the AI value pool than intermediaries.
• Consider a diagonal call structure on GOOG or LLY into the next 6-9 months to monetize the stock’s tendency to grind higher while limiting downside if AI enthusiasm pauses. Use this where implied vol is not overly rich versus realized moves.
• Avoid chasing NVDA/UBER on this read-through; their mention is incidental. The second-order winner is likely the platform owner, not the infrastructure or dependent partner, so use any strength there to rotate into the higher-conviction compounders.